Home

Search Abstracts

Browse Oral Sessions

Browse Poster Sessions

Session 188-Poster Abstracts HIV Prevention Trials: HIV Test Performance, Pregnancy, Bone Toxicity, and Resistance Tuesday, 2-4 pm; Poster Hall     1058 Frequency of False Positive HIV Rapid Tests in a Cohort of Men and Women Receiving PrEP—Implications for Programmatic Roll-out: Kenya and Uganda Patrick Ndase*1, C Celum1, D Donnell1,2, C Farquhar1, K Fife3, A Ronald4, R Coombs1, L Kidoguchi1, J Baeten1, and Partners PrEP Study Team 1Univ of Washington, Seattle, US; 2Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 3Indiana Univ, Indianapolis, US; and 4Univ of Manitoba, Winnipeg, Canada     1059 Pregnant Women Have Poorer Adherence to Study Gel in CAPRISA 004, a Phase IIB Randomized Controlled Trial of 1% TenofovirF Gel Lynn Matthews*1,2, S Sibeko3, L Mansoor3, N Yende-Zuma3, D Bangsberg1,4, and Q Abdool Karim3 1Massachusetts Gen Hosp, Boston, US; 2Beth Israel Deaconess Med Ctr, Boston, MA, US; 3Ctr for the AIDS Prgm of Res in South Africa, Durban; and 4Mbarara Univ of Sci and Tech, Uganda     1060 Pregnancy Incidence and Birth Outcomes among in a Clinical Trial of PrEP: Uganda and Kenya Nelly Mugo*1,2, C Celum1, D Donnell1,3, J Campbell4, E Bukusi1,5, G John-Stewart1, J Kiarie1,2, E Were6, K Thomas1, J Baeten1, and Partners PrEP Study Team 1Univ of Washington, Seattle, US; 2Univ of Nairobi, Kenya; 3Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 4CDC, Entebbe, Uganda; 5Kenya Med Res Inst, Nairobi; and 6Moi Univ, Eldoret, Kenya     1061 PrEP-C: A Risk Reduction Strategy For HIV– Women with HIV+ Partners Stephen Taylor*1, J Whetham2, C McInnes1, L Charlewood2, E Payne1, T Kieth2, R Howell2, J Home1, D White1, and Y Gilleece2 1Birmingham Heartlands Hosp, UK and 2Brighton and Sussex Univ Hosp NHS Trust, Brighton, UK     1062 Impact of the Between-dose Loss in Protection on the Efficacy of Oral PrEP with Different Dosing Regimens Dobromir Dimitrov*1,2, B Masse1,3, S Holte1,2, and E Brown1,2 1Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 2Univ of Washington, Seattle, US; and 3Univ of Montreal, Canada     1063 Tenofovir Resistance Mutation Frequencies Assessed by Deep Pyrosequencing of Plasma Virus from Breakthrough HIV Infections: CAPRISA 004 Microbicide Trial Will Fischer*1, G Hunt2, S Sibeko3, V Naranbhai3, Q Abdool Karim3, S Abdool Karim3, L Morris2, and B Korber1,4 1Los Alamos Natl Lab, NM, US; 2Natl Inst for Communicable Diseases, Johannesburg, South Africa; 3Ctr for the AIDS Prgm of Res in South Africa, Univ of KwaZulu-Natal, Durban; and 4Santa Fe Inst, NM, US     1064 MTN-009—Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials: KwaZulu-Natal, South Africa Urvi Parikh*1, P Kiepiela2, S Ganesh2, K Gomez Feliciano3, S Horn3, K Eskay1, C Kelly4, L Soto-Torres5, G Ramjee2, J Mellors1, on behalf of the MTN-009 Protocol Team 1Univ of Pittsburgh, PA, US; 2South African MRC, Durban; 3FHI 360, Durham, NC, US; 4Statistical Ctr for HIV/AIDS Res & Prevention, Seattle, WA, US; and 5NIAID, NIH, Bethesda, MD, US